Prognostic Significance of miRNA Subtypes in Melanoma: A Survival Analysis and Correlation with Treatment Response Across Patient Stages DOI Creative Commons

Mihaela Prodan,

Alis Dema,

Bianca Natarâș

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(12), P. 2809 - 2809

Published: Dec. 11, 2024

Background and Objectives: Melanoma remains a leading cause of skin cancer mortality despite advancements in targeted therapies immunotherapies. MicroRNAs (miRNAs) have emerged as potential biomarkers for prognosis treatment response. This study aims to analyze survival outcomes according various miRNA subtypes, assess the association between specific miRNAs response, include patient staging evaluate their prognostic significance. Methods: A retrospective cohort was conducted on 90 patients from Pius Brinzeu County Emergency Clinical Hospital, Timisoara, 2019 2022. The included 45 with advanced-stage melanoma benign nevi. expression levels were quantified using miRNeasy Kit Human Cancer PathwayFinder miScript PCR Array. Survival analysis performed Kaplan–Meier method, Cox proportional hazards models used impact survival. Logistic regression analyzed markers adjusting staging. Results: Elevated hsa-miR-200a-3p hsa-miR-335-5p significantly associated poorer overall (p < 0.01), particularly stage III IV patients. Conversely, higher hsa-miR-451a correlated improved rates = 0.02). Patients increased hsa-miR-29b-3p showed better response immunotherapy (OR 2.35, 95% CI: 1.15–4.79). Multivariate confirmed that independent predictors Conclusions: Specific subtypes are significant melanoma, influencing responses across different stages. Incorporating profiling into clinical practice could enhance personalized strategies improve prognoses.

Language: Английский

Liquid biopsy for diagnostic and prognostic evaluation of melanoma DOI Creative Commons

Nicholas Slusher,

Nicholas Jones, T. NONAKA

et al.

Frontiers in Cell and Developmental Biology, Journal Year: 2024, Volume and Issue: 12

Published: Aug. 2, 2024

Melanoma is the most aggressive form of skin cancer, and majority cases are associated with chronic or intermittent sun exposure. The incidence melanoma has grown exponentially over last 50 years, especially in populations fairer skin, at lower altitudes geriatric populations. gold standard for diagnosis performing an excisional biopsy full resection incisional tissue biopsy. However, due to their invasiveness, conventional techniques not suitable continuous disease monitoring. Utilization liquid represent substantial promise early detection melanoma. Through this procedure, tumor-specific components shed into circulation can be analyzed only but also treatment selection risk assessment. Additionally, significantly less invasive than offers a novel way monitor response relapse, predicting metastasis.

Language: Английский

Citations

4
Extracellular vesicles and microRNAs in cancer progression DOI
Nicola Salvatore Orefice, Gianluca Petrillo,

Claudia Pignataro

et al.

Advances in clinical chemistry, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

0
Circulating MicroRNAs: functional biomarkers for melanoma prognosis and treatment DOI Creative Commons
Su Yin Lim,

Suzanah C. Boyd,

Russell J. Diefenbach

et al.

Molecular Cancer, Journal Year: 2025, Volume and Issue: 24(1)

Published: March 28, 2025

MicroRNAs (miRNAs) hold significant promise as circulating cancer biomarkers and unlike many other molecular markers, they can provide valuable insights that extend beyond tumour biology. The expression of miRNAs may parallel the cellular composition dynamic activity within microenvironment reveal systemic immune responses. functional complexity miRNAs-where a single miRNA regulate multiple messenger RNAs (mRNAs) to fine tune fundamental processes, mRNA be targeted by miRNAs-underscores their broad significance impact. However, this poses challenges for translating research into clinical practice. In melanoma, specific signatures have shown notable diagnostic, prognostic predictive value, with lineage-specific immune-related frequently identified markers. review, we explore role potential in highlight current status advances required translate therapeutic opportunities.

Language: Английский

Citations

0
Amelanotic Melanoma: Diagnostic Challenges, Treatment Innovations, and the Emerging Role of AI in Early Detection DOI Creative Commons
Diala Ra’Ed Kamal Kakish, Jehad Feras AlSamhori, Ahmad Ayman

et al.

Journal of Medicine Surgery and Public Health, Journal Year: 2025, Volume and Issue: unknown, P. 100189 - 100189

Published: March 1, 2025

Language: Английский

Citations

0
Amelanotic Melanoma—Biochemical and Molecular Induction Pathways DOI Open Access
Piotr Misiąg, Klaudia Molik, Monika Kisielewska

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(21), P. 11502 - 11502

Published: Oct. 26, 2024

Amelanotic melanoma (AM) is a subtype of hypomelanotic or completely amelanotic melanoma. AM rare that exhibits higher recurrence rate and aggressiveness as well worse surveillance than typical shows dysregulation melanin production, cell cycle control, apoptosis pathways. Knowing these pathways has an application in medicine due to targeted therapies based on the inhibiting elements abovementioned Therefore, we summarized discussed biochemical molecular induction personalized approaches, clinical management, future directions fact relatively rare. commonly misdiagnosed. Hence, role biomarkers becoming significant. Nonetheless, there shortage specific AM. BRAF, NRAS, c-KIT genes are main targets therapy. However, BRAF KIT varied among studies. inhibitors combined with MAK demonstrate better results. Immune checkpoint targeting CTLA-4 programmed death receptor 1 (PD-1) show outcomes separately. Fecal microbiota transplantation may overcome resistance immune therapy Immune-modulatory vaccines against indoleamine 2,3-dioxygenase (IDO) PD ligand (PD-L1) nivolumab be efficient treatment.

Language: Английский

Citations

3
Prognostic Significance of miRNA Subtypes in Melanoma: A Survival Analysis and Correlation with Treatment Response Across Patient Stages DOI Creative Commons

Mihaela Prodan,

Alis Dema,

Bianca Natarâș

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(12), P. 2809 - 2809

Published: Dec. 11, 2024

Background and Objectives: Melanoma remains a leading cause of skin cancer mortality despite advancements in targeted therapies immunotherapies. MicroRNAs (miRNAs) have emerged as potential biomarkers for prognosis treatment response. This study aims to analyze survival outcomes according various miRNA subtypes, assess the association between specific miRNAs response, include patient staging evaluate their prognostic significance. Methods: A retrospective cohort was conducted on 90 patients from Pius Brinzeu County Emergency Clinical Hospital, Timisoara, 2019 2022. The included 45 with advanced-stage melanoma benign nevi. expression levels were quantified using miRNeasy Kit Human Cancer PathwayFinder miScript PCR Array. Survival analysis performed Kaplan–Meier method, Cox proportional hazards models used impact survival. Logistic regression analyzed markers adjusting staging. Results: Elevated hsa-miR-200a-3p hsa-miR-335-5p significantly associated poorer overall (p < 0.01), particularly stage III IV patients. Conversely, higher hsa-miR-451a correlated improved rates = 0.02). Patients increased hsa-miR-29b-3p showed better response immunotherapy (OR 2.35, 95% CI: 1.15–4.79). Multivariate confirmed that independent predictors Conclusions: Specific subtypes are significant melanoma, influencing responses across different stages. Incorporating profiling into clinical practice could enhance personalized strategies improve prognoses.

Language: Английский

Citations

1